Emerging Therapeutic Strategies in the Management of Anemia in Patients with CKD

 

 

PROGRAM OVERVIEW

Patients with CKD and anemia experience substantially increased burdens to morbidity and mortality.  The use of erythropoiesis-stimulating agents (ESAs) and iron supplementation are the mainstays of therapy, yet ESA has been associated with increased cardiovascular adverse events.  Increased understanding of hypoxia-inducible factors (HIFs) have led to the development of novel therapies, HIF-PHIs, that work by simulating hypoxia in cells, thereby stimulating EPO synthesis and improving iron metabolism and mobilization through recduced hepcidin levels. Four HIF-PHIs are currently undergoing late-stage development, with one agent already approved to treat anemia in patients with CKD in China. It is important that healthcare providers are updated on the clinical trial data of these novel therapies so they are better prepared to integrate these agents in to clinical practice upon FDA approval.

FACULTY

Andrew Howard, MD, FACP
Metropolitan Nephrology Associates
Senior Consultant to the CMO
Fresenius Kidney Care

Release date: February 24, 2020
Expiration date: February 24, 2021
Estimated time to complete activity: 0.75 hour(s)

 

TARGET AUDIENCE

This activity is intended for nephrology specialty HCPs that manage patients with anemia in CKD.

LEARNING OBJECTIVES
  • Describe the prevalence of and burden associated with anemia in patients with chronic kidney disease (CKD), particularly those who are hyporesponsive to Erythropoietin Stimulating Agents (ESA) therapy
  • Discuss the pathogenic mechanisms involved in anemia associated with CIKD, including the roles of inflamation, hepcidin, and the HIF pathway
  • Explain the clinical utility of measuring hepcidin levels in patiens with anemia and CKD
  • Review outcomes from clinical trials evaluating the use of HIF-PHIs to treat anemia in patients with CKD
DIRECTIONS TO THE LEARNER

There are no fees for participating and receiving CME credit for this activity.  During the period of February 24, 2020 through February 24, 2021 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pre-test
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

MEDIA

Internet

ACCREDITATION STATEMENT

Integrity Continuing Educaition is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits(s)TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.

DISCLOSURES OF CONFLICTS OF INTEREST

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity.  All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/ planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Andrew Howard, MD, FACP
Consulting: Fresenius Kidney Care

Integrity Continuing Education, Inc. Planners/managers do not have any conflicts of interest to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  Integrity Continuing Education, Inc. and AstraZeneca Pharmaceuticals LP do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity provided by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliations(s), street address, telephone number, fax number, and… (continued).

MINIMUM SYSTEM REQUIREMENTS

Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10
Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.

DISCLAIMER

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgement of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc.

SUPPORTER ACKNOWLEDGEMENT

Supported by an educational grant from AstraZeneca Pharmaceuticals, LP.

Continue to Pretest